PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PSTV is not a good buy right now for an impatient investor. The chart is in a strong downtrend (bearish moving-average stack), momentum is still negative (MACD below zero), and there is no Intellectia buy signal to justify stepping in despite the oversold RSI. With recent dilution driving repeated price-target cuts and no near-term news catalyst this week, the higher-probability path is continued weakness/volatility rather than an immediate tradable rebound.
Trend/momentum: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend. MACD histogram is -0.0113 (below 0) and only negatively contracting, which suggests downside momentum is easing but not reversed.
Mean-reversion/oversold: RSI_6 at 18.5 is deeply oversold, so a short bounce is possible, but oversold conditions can persist in micro-cap downtrends—this is not a reliable buy trigger without confirmation.
Key levels: Price (0.2301) is sitting right on S1 (0.232). A clean break below S1 increases risk of a move toward S2 (0.209). For a credible reversal attempt, bulls would typically need to reclaim the pivot (0.269) and then challenge R1 (0.306).
Pattern-based short-term odds provided: Similar-pattern projection implies ~-6.25% over the next month, reinforcing the bearish bias.
Intellectia Proprietary Trading Signals
Latest quarter: 2025/Q3. Revenue fell to $1.397M (-4.05% YoY), indicating soft top-line momentum. Net income improved to -$4.423M (loss narrowed ~53.9% YoY), but EPS worsened to -$0.04 (down -89.19% YoY per snapshot), highlighting that per-share results remain pressured (likely impacted by share count/dilution dynamics). Overall: mixed—loss narrowing, but revenue and EPS trends are not strong enough to offset the current technical weakness.
Recent trend: Buy ratings maintained, but price targets were cut multiple times due to dilution from financing. On 2026-01-23, Maxim cut PT to $1.50 from $3 (Buy maintained) and H.C. Wainwright cut PT to $1 from $2 (Buy maintained); H.C. Wainwright also cut PT to $2 from $3 on 2025-11-03 (Buy maintained).
Wall Street pros: Bull case centers on upcoming clinical milestones (ReSPECT-LM data timing and progression toward a potentially pivotal study) and a “catalyst-rich” 2026. Wall Street cons: The dominant near-term concern is dilution/financing overhang, which lowers per-share upside and has already forced PT reductions.
